Glioblastoma Explained

Glioblastoma
Synonyms:Glioblastoma multiforme
Field:Neuro-oncology, neurosurgery
Symptoms:Initially nonspecific, headaches, personality changes, nausea, symptoms similar to a stroke
Onset:~64 years old
Causes:Usually unclear
Risks:Genetic disorders (neurofibromatosis, Li–Fraumeni syndrome), previous radiation therapy
Diagnosis:CT scan, MRI scan, tissue biopsy
Prevention:Unknown
Treatment:Surgery, chemotherapy, radiation
Medication:Temozolomide, steroids
Prognosis:Life expectancy ~ 12 months with treatment (5 year survival <10%)
Frequency:3 per 100,000 per year

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival.[1] [2] [3] Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

The cause of most cases of glioblastoma is not known.[4] Uncommon risk factors include genetic disorders, such as neurofibromatosis and Li–Fraumeni syndrome, and previous radiation therapy.[4] Glioblastomas represent 15% of all brain tumors.[5] They are thought to arise from astrocytes.[6] The diagnosis typically is made by a combination of a CT scan, MRI scan, and tissue biopsy.[5]

There is no known method of preventing the cancer. Treatment usually involves surgery, after which chemotherapy and radiation therapy are used.[7] The medication temozolomide is frequently used as part of chemotherapy.[7] [8] High-dose steroids may be used to help reduce swelling and decrease symptoms.[5] Surgical removal (decompression) of the tumor is linked to increased survival, but only by some months.[9]

Despite maximum treatment, the cancer almost always recurs.[7] The typical duration of survival following diagnosis is 10–13 months, with fewer than 5–10% of people surviving longer than five years.[10] [11] [12] Without treatment, survival is typically three months.[13] It is the most common cancer that begins within the brain and the second-most common brain tumor, after meningioma, which is benign in most cases.[1] [14] About 3 in 100,000 people develop the disease per year.[7] The average age at diagnosis is 64, and the disease occurs more commonly in males than females.[4] [7]

Tumors of the central nervous system are the 10th leading cause of death worldwide, with up to 90% being brain tumors.[15] Glioblastoma multiforme (GBM) is derived from astrocytes and accounts for 49% of all malignant central nervous system tumors, making it the most common form of central nervous system cancer. Despite countless efforts to develop new therapies for GBM over the years, the median survival rate of GBM patients worldwide is a dismal 8 months, with radiation and chemotherapy standard-of-care treatment beginning shortly after diagnosis only improving median survival length to around 14 months and a five-year survival rate of 5–10%. Similarly, the five-year survival rate for individuals with any form of primary malignant brain tumor is only 20%.[16] The challenges associated with successfully treating brain cancers are numerous. In the simplest terms, brain tumors often occur in areas too difficult or dangerous to surgically resect, and most drug therapeutics are incapable of crossing the blood-brain barrier in sufficient quantities to stop tumor growth. Furthermore, while stereotactic radiosurgery-based approaches have proved to be effective for ablating a variety of brain tumors visible to MRI and other neuroimaging, metastatic brain cancers maintain high recurrence rates, with GBM recurrence seemingly inevitable.

Signs and symptoms

Common symptoms include seizures, headaches, nausea and vomiting, memory loss, changes to personality, mood or concentration, and localized neurological problems.[17] The kinds of symptoms produced depend more on the location of the tumor than on its pathological properties. The tumor can start producing symptoms quickly, but occasionally is an asymptomatic condition until it reaches an enormous size.[18]

Risk factors

The cause of most cases is unclear. The best known risk factor is exposure to ionizing radiation, and CT scan radiation is an important cause.[19] [20] About 5% develop from certain hereditary syndromes.[17]

Genetics

Uncommon risk factors include genetic disorders such as neurofibromatosis, Li–Fraumeni syndrome, tuberous sclerosis, or Turcot syndrome.[17] Previous radiation therapy is also a risk.[4] [7] For unknown reasons, it occurs more commonly in males.[21]

Environmental

Other associations include exposure to smoking, pesticides, and working in petroleum refining or rubber manufacturing.[17]

Glioblastoma has been associated with the viruses SV40,[22] HHV-6,[23] [24] and cytomegalovirus (CMV).[25] Infection with an oncogenic CMV may even be necessary for the development of glioblastoma.[26] [27]

Other

Research has been done to see if consumption of cured meat is a risk factor. No risk had been confirmed as of 2003.[28] Similarly, exposure to formaldehyde, and residential electromagnetic fields, such as from cell phones and electrical wiring within homes, have been studied as risk factors. As of 2015, they had not been shown to cause GBM.[17] [29] [30]

Pathogenesis

The cellular origin of glioblastoma is unknown. Because of the similarities in immunostaining of glial cells and glioblastoma, gliomas such as glioblastoma have long been assumed to originate from glial-type stem cells found in the subventricular zone. More recent studies suggest that astrocytes, oligodendrocyte progenitor cells, and neural stem cells could all serve as the cell of origin.[31] [32]

GBMs usually form in the cerebral white matter, grow quickly, and can become very large before producing symptoms. Since the function of glial cells in the brain is to support neurons, they have the ability to divide, to enlarge, and to extend cellular projections along neurons and blood vessels. Once cancerous, these cells are predisposed to spread along existing paths in the brain, typically along white-matter tracts, blood vessels and the perivascular space.[33] The tumor may extend into the meninges or ventricular wall, leading to high protein content in the cerebrospinal fluid (CSF) (> 100 mg/dl), as well as an occasional pleocytosis of 10 to 100 cells, mostly lymphocytes. Malignant cells carried in the CSF may spread (rarely) to the spinal cord or cause meningeal gliomatosis. However, metastasis of GBM beyond the central nervous system is extremely unusual. About 50% of GBMs occupy more than one lobe of a hemisphere or are bilateral. Tumors of this type usually arise from the cerebrum and may exhibit the classic infiltration across the corpus callosum, producing a butterfly (bilateral) glioma.[34]

Glioblastoma classification

Brain tumor classification has been traditionally based on histopathology at macroscopic level, measured in hematoxylin-eosin sections. The World Health Organization published the first standard classification in 1979[35] and has been doing so since. The 2007 WHO Classification of Tumors of the Central Nervous System[36] was the last classification mainly based on microscopy features. The new 2016 WHO Classification of Tumors of the Central Nervous System[37] was a paradigm shift: some of the tumors were defined also by their genetic composition as well as their cell morphology.

In 2021, the fifth edition of the WHO Classification of Tumors of the Central Nervous System was released. This update eliminated the classification of secondary glioblastoma and reclassified those tumors as Astrocytoma, IDH mutant, grade 4. Only tumors that are IDH wild type are now classified as glioblastoma.[38]

Features of glioblastoma, IDH wildtype, WHO 4[39]
SynonymsGlioblastoma, GBM
Cell of originAstrocyte
Median age at diagnosis~62 years
Male:Female ratio1.42:1
Median length of clinical history at diagnosis4 months
Median overall survival
Surgery + radiotherapy9.9 months
Surgery + radiotherapy + chemotherapy15 months
LocationUsually supratentorial, rarely cerebellum or spine
Necrosis and microvascular proliferationExtensive
Associated molecular/genetic mutationsTERT promoter mutation, combined gain of chromosome 7 and loss of chromosome 10; EGFR amplification

Molecular alterations

There are currently three molecular subtypes of glioblastoma that were identified based on gene expression:[40]

Initial analyses of gene expression had revealed a fourth neural subtype.[43] However, further analyses revealed that this subtype is non-tumor specific and is potential contamination caused by the normal cells.[40]

Many other genetic alterations have been described in glioblastoma, and the majority of them are clustered in two pathways, the RB and the PI3K/AKT.[45] 68–78% and 88% of Glioblastomas have alterations in these pathways, respectively.

Another important alteration is methylation of MGMT, a "suicide" DNA repair enzyme. Methylation impairs DNA transcription and expression of the MGMT gene. Since the MGMT enzyme can repair only one DNA alkylation due to its suicide repair mechanism, reserve capacity is low and methylation of the MGMT gene promoter greatly affects DNA-repair capacity.[46] MGMT methylation is associated with an improved response to treatment with DNA-damaging chemotherapeutics, such as temozolomide.[47]

Studies using genome-wide profiling have revealed glioblastomas to have a remarkable genetic variety.[48]

At least three distinct paths in the development of Glioblastomas have been identified with the aid of molecular investigations.

Cancer stem cells

Glioblastoma cells with properties similar to progenitor cells (glioblastoma cancer stem cells) have been found in glioblastomas. Their presence, coupled with the glioblastoma's diffuse nature results in difficulty in removing them completely by surgery, and is therefore believed to be the possible cause behind resistance to conventional treatments, and the high recurrence rate.[50] Glioblastoma cancer stem cells share some resemblance with neural progenitor cells, both expressing the surface receptor CD133.[51] CD44 can also be used as a cancer stem cell marker in a subset of glioblastoma tumour cells.[52] Glioblastoma cancer stem cells appear to exhibit enhanced resistance to radiotherapy and chemotherapy mediated, at least in part, by up-regulation of the DNA damage response.[53]

Metabolism

The IDH1 gene encodes for the enzyme isocitrate dehydrogenase 1 and is not mutated in glioblastoma. As such, these tumors behave more aggressively compared to IDH1-mutated astrocytomas.

Ion channels

Furthermore, GBM exhibits numerous alterations in genes that encode for ion channels, including upregulation of gBK potassium channels and ClC-3 chloride channels. By upregulating these ion channels, glioblastoma tumor cells are hypothesized to facilitate increased ion movement over the cell membrane, thereby increasing H2O movement through osmosis, which aids glioblastoma cells in changing cellular volume very rapidly. This is helpful in their extremely aggressive invasive behavior because quick adaptations in cellular volume can facilitate movement through the sinuous extracellular matrix of the brain.[54]

MicroRNA

As of 2012, RNA interference, usually microRNA, was under investigation in tissue culture, pathology specimens, and preclinical animal models of glioblastoma.[55] Additionally, experimental observations suggest that microRNA-451 is a key regulator of LKB1/AMPK signaling in cultured glioma cells[56] and that miRNA clustering controls epigenetic pathways in the disease.[57]

Tumor vasculature

GBM is characterized by abnormal vessels that present disrupted morphology and functionality.[58] The high permeability and poor perfusion of the vasculature result in a disorganized blood flow within the tumor and can lead to increased hypoxia, which in turn facilitates cancer progression by promoting processes such as immunosuppression.[59]

Diagnosis

When viewed with MRI, glioblastomas often appear as ring-enhancing lesions. The appearance is not specific, however, as other lesions such as abscess, metastasis, tumefactive multiple sclerosis, and other entities may have a similar appearance.[60] Definitive diagnosis of a suspected GBM on CT or MRI requires a stereotactic biopsy or a craniotomy with tumor resection and pathologic confirmation. Because the tumor grade is based upon the most malignant portion of the tumor, biopsy or subtotal tumor resection can result in undergrading of the lesion. Imaging of tumor blood flow using perfusion MRI and measuring tumor metabolite concentration with MR spectroscopy may add diagnostic value to standard MRI in select cases by showing increased relative cerebral blood volume and increased choline peak, respectively, but pathology remains the gold standard for diagnosis and molecular characterization.

Distinguishing glioblastoma from high-grade astrocytoma is important. These tumors occur spontaneously (de novo) and have not progressed from a lower-grade glioma, as in high-grade astrocytomas Glioblastomas have a worse prognosis and different tumor biology, and may have a different response to therapy, which makes this a critical evaluation to determine patient prognosis and therapy.[61] [62] Astrocytomas carry a mutation in IDH1 or IDH2, whereas this mutation is not present in glioblastoma. Thus, IDH1 and IDH2 mutations are a useful tool to distinguish glioblastomas from astrocytomas, since histopathologically they are similar and the distinction without molecular biomarkers is unreliable. IDH-wildtype glioblastomas usually have lower OLIG2 expression compared with IDH-mutant lower grade astrocytomas.[63] In patients aged over 55 years with a histologically typical glioblastoma, without a pre-existing lower grade glioma, with a non-midline tumor location and with retained nuclear ATRX expression, immunohistochemical negativity for IDH1 R132H suffices for the classification as IDH-wild-type glioblastoma. In all other instances of diffuse gliomas, a lack of IDH1 R132H immunopositivity should be followed by IDH1 and IDH2 DNA sequencing to detect or exclude the presence of non-canonical mutations. IDH-wild-type diffuse astrocytic gliomas without microvascular proliferation or necrosis should be tested for EGFR amplification, TERT promoter mutation and a +7/–10 cytogenetic signature as molecular characteristics of IDH-wild-type glioblastomas.

Prevention

There are no known methods to prevent glioblastoma.[7] It is the case for most gliomas, unlike for some other forms of cancer, that they happen without previous warning and there are no known ways to prevent them.[64]

Treatment

Treating glioblastoma is difficult due to several complicating factors:[65]

Treatment of primary brain tumors consists of palliative (symptomatic) care and therapies intended to improve survival.

Symptomatic therapy

Supportive treatment focuses on relieving symptoms and improving the patient's neurologic function. The primary supportive agents are anticonvulsants and corticosteroids.

Surgery

Surgery is the first stage of treatment of glioblastoma. An average GBM tumor contains 1011 cells, which is on average reduced to 109 cells after surgery (a reduction of 99%). Benefits of surgery include resection for a pathological diagnosis, alleviation of symptoms related to mass effect, and potentially removing disease before secondary resistance to radiotherapy and chemotherapy occurs.[67]

The greater the extent of tumor removal, the better. In retrospective analyses, removal of 98% or more of the tumor has been associated with a significantly longer healthier time than if less than 98% of the tumor is removed.[68] The chances of near-complete initial removal of the tumor may be increased if the surgery is guided by a fluorescent dye known as 5-aminolevulinic acid.[69] [70] GBM cells are widely infiltrative through the brain at diagnosis, and despite a "total resection" of all obvious tumor, most people with GBM later develop recurrent tumors either near the original site or at more distant locations within the brain. Other modalities, typically radiation and chemotherapy, are used after surgery in an effort to suppress and slow recurrent disease through damaging the DNA of rapidly proliferative GBM cells.[71]

Between 60-85% of glioblastoma patients report cancer-related cognitive impairments following surgery, which refers to problems with executive functioning, verbal fluency, attention, speed of processing.[72] [73] [74] These symptoms may be managed with cognitive behavioral therapy,[75] [76] physical exercise, yoga and meditation.[77]

Radiotherapy

Subsequent to surgery, radiotherapy becomes the mainstay of treatment for people with glioblastoma. It is typically performed along with giving temozolomide.[78] A pivotal clinical trial carried out in the early 1970s showed that among 303 GBM patients randomized to radiation or best medical therapy, those who received radiation had a median survival more than double those who did not.[79] Subsequent clinical research has attempted to build on the backbone of surgery followed by radiation. Whole-brain radiotherapy does not improve when compared to the more precise and targeted three-dimensional conformal radiotherapy.[80] A total radiation dose of 60–65 Gy has been found to be optimal for treatment.[81]

GBM tumors are well known to contain zones of tissue exhibiting hypoxia, which are highly resistant to radiotherapy. Various approaches to chemotherapy radiosensitizers have been pursued, with limited success ., newer research approaches included preclinical and clinical investigations into the use of an oxygen diffusion-enhancing compound such as trans sodium crocetinate as radiosensitizers,[82] and a clinical trial was underway.[83] Boron neutron capture therapy has been tested as an alternative treatment for glioblastoma, but is not in common use.

Chemotherapy

Most studies show no benefit from the addition of chemotherapy. However, a large clinical trial of 575 participants randomized to standard radiation versus radiation plus temozolomide chemotherapy showed that the group receiving temozolomide survived a median of 14.6 months as opposed to 12.1 months for the group receiving radiation alone.[84] This treatment regimen is now standard for most cases of glioblastoma where the person is not enrolled in a clinical trial.[85] [86] Temozolomide seems to work by sensitizing the tumor cells to radiation, and appears more effective for tumors with MGMT promoter methylation.[87] High doses of temozolomide in high-grade gliomas yield low toxicity, but the results are comparable to the standard doses.[88] Antiangiogenic therapy with medications such as bevacizumab control symptoms, but do not appear to affect overall survival in those with glioblastoma. A 2018 systematic review found that the overall benefit of anti-angiogenic therapies was unclear.[89] In elderly people with newly diagnosed glioblastoma who are reasonably fit, concurrent and adjuvant chemoradiotherapy gives the best overall survival but is associated with a greater risk of haematological adverse events than radiotherapy alone.[90]

Immunotherapy

Phase 3 clinical trials of immunotherapy treatments for glioblastoma have largely failed.[91]

Other procedures

Alternating electric field therapy is an FDA-approved therapy for newly diagnosed[92] and recurrent glioblastoma.[93] In 2015, initial results from a phase-III randomized clinical trial of alternating electric field therapy plus temozolomide in newly diagnosed glioblastoma reported a three-month improvement in progression-free survival, and a five-month improvement in overall survival compared to temozolomide therapy alone,[94] [95] representing the first large trial in a decade to show a survival improvement in this setting.[95] Despite these results, the efficacy of this approach remains controversial among medical experts.[96] However, increasing understanding of the mechanistic basis through which alternating electric field therapy exerts anti-cancer effects and results from ongoing phase-III clinical trials in extracranial cancers may help facilitate increased clinical acceptance to treat glioblastoma in the future.[97]

Prognosis

The most common length of survival following diagnosis is 10 to 13 months (although recent research points to a median survival rate of 15 months),[98] [99] with fewer than 1–3% of people surviving longer than five years.[4] [12] [100] In the United States between 2012 and 2016 five-year survival was 6.8%.[12] Without treatment, survival is typically three months.[13] Complete cures are extremely rare, but have been reported.[101]

Increasing age (> 60 years) carries a worse prognostic risk. Death is usually due to widespread tumor infiltration with cerebral edema and increased intracranial pressure.[102]

A good initial Karnofsky performance score (KPS) and MGMT methylation are associated with longer survival.[102] A DNA test can be conducted on glioblastomas to determine whether or not the promoter of the MGMT gene is methylated. Patients with a methylated MGMT promoter have longer survival than those with an unmethylated MGMT promoter, due in part to increased sensitivity to temozolomide.[103]

Long-term benefits have also been associated with those patients who receive surgery, radiotherapy, and temozolomide chemotherapy.[102] However, much remains unknown about why some patients survive longer with glioblastoma. Age under 50 is linked to longer survival in GBM, as is 98%+ resection and use of temozolomide chemotherapy and better KPSs. A recent study confirms that younger age is associated with a much better prognosis, with a small fraction of patients under 40 years of age achieving a population-based cure. Cure is thought to occur when a person's risk of death returns to that of the normal population, and in GBM, this is thought to occur after 10 years.[104]

UCLA Neuro-oncology publishes real-time survival data for patients with this diagnosis.[105]

According to a 2003 study, GBM prognosis can be divided into three subgroups dependent on KPS, the age of the patient, and treatment.[106]

Recursive partitioning analysis
(RPA) class 		Definition Historical Median Survival Time Historical 1-Year Survival Historical 3-Year Survival Historical 5-Year Survival
III Age < 50, KPS ≥ 90 17.1 months 70% 20% 14%
IV Age < 50, KPS < 90 11.2 months 46% 7% 4%
Age ≥ 50, KPS ≥ 70, surgical removal with good neurologic function
V + VI Age ≥ 50, KPS ≥ 70, surgical removal with poor neurologic function Age ≥ 50, KPS ≥ 70, no surgical removal 7.5 months 28% 1%0%
Age ≥ 50, KPS < 70

Epidemiology

About three per 100,000 people develop the disease a year,[7] although regional frequency may be much higher.[107] The frequency in England doubled between 1995 and 2015.[108]

It is the second-most common central nervous system tumor after meningioma.[14] It occurs more commonly in males than females.[4] [7] Although the median age at diagnosis is 64,[4] [7] in 2014, the broad category of brain cancers was second only to leukemia in people in the United States under 20 years of age.[109]

History

The term glioblastoma multiforme was introduced in 1926 by Percival Bailey and Harvey Cushing, based on the idea that the tumor originates from primitive precursors of glial cells (glioblasts), and the highly variable appearance due to the presence of necrosis, hemorrhage, and cysts (multiform).[110]

Research

Gene therapy

Gene therapy has been explored as a method to treat glioblastoma, and while animal models and early-phase clinical trials have been successful, as of 2017, all gene-therapy drugs that had been tested in phase-III clinical trials for glioblastoma had failed.[111] [112] [113] Scientists have developed the core–shell nanostructured LPLNP-PPT (long persistent luminescence nanoparticles. PPT refers to polyetherimide, PEG and trans-activator of transcription, and TRAIL is the human tumor necrosis factor-related apoptosis-induced ligand[114]) for effective gene delivery and tracking, with positive results. This is a TRAIL ligand that has been encoded to induce apoptosis of cancer cells, more specifically glioblastomas. Although this study was still in clinical trials in 2017, it has shown diagnostic and therapeutic functionalities, and will open great interest for clinical applications in stem-cell-based therapy.[115]

Other gene therapy approaches has also been explored in the context of glioblastoma, including suicide gene therapy. Suicide gene therapy is a two step approach which includes the delivery of a foreign enzyme-gene to the cancer cells followed by activation with an pro-drug causing toxicities in the cancer-cells which induces cell death. This approach have had success in animal models and small clinical studied but could not show survival benefit in larger clinical studies. Using new more efficient delivery vectors and suicide gene-prodrug systems could improve the clinical benefit from these types of therapies.[116]

Oncolytic virotherapy

Oncolytic virotherapy is an emerging novel treatment that is under investigation both at preclinical and clinical stages. Several viruses including herpes simplex virus, adenovirus, poliovirus, and reovirus are currently being tested in phases I and II of clinical trials for glioblastoma therapy and have shown to improve overall survival.[117]

Intranasal drug delivery

Direct nose-to-brain drug delivery is being explored as a means to achieve higher, and hopefully more effective, drug concentrations in the brain.[118] [119] A clinical phase-I/II study with glioblastoma patients in Brazil investigated the natural compound perillyl alcohol for intranasal delivery as an aerosol. The results were encouraging[118] [120] [121] and, as of 2016, a similar trial has been initiated in the United States.

See also

External links

Notes and References

  1. Bleeker FE, Molenaar RJ, Leenstra S . Recent advances in the molecular understanding of glioblastoma . Journal of Neuro-Oncology . 108 . 1 . 11–27 . May 2012 . 22270850 . 3337398 . 10.1007/s11060-011-0793-0 .
  2. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M . Management of glioblastoma: State of the art and future directions . CA . 70 . 4 . 299–312 . July 2020 . 32478924 . 10.3322/caac.21613 . Wiley . free . 219170898 . 10536/DRO/DU:30138185 .
  3. Tran B, Rosenthal MA . Survival comparison between glioblastoma multiforme and other incurable cancers . Journal of Clinical Neuroscience . 17 . 4 . 417–421 . April 2010 . 20167494 . 10.1016/j.jocn.2009.09.004 . 5492993 .
  4. Book: World Cancer Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 5.16 .
  5. Young RM, Jamshidi A, Davis G, Sherman JH . Current trends in the surgical management and treatment of adult glioblastoma . Annals of Translational Medicine . 3 . 9 . 121 . June 2015 . 26207249 . 4481356 . 10.3978/j.issn.2305-5839.2015.05.10 .
  6. Book: World Cancer Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 3.8 .
  7. Gallego O . Nonsurgical treatment of recurrent glioblastoma . Current Oncology . 22 . 4 . e273–e281 . August 2015 . 26300678 . 4530825 . 10.3747/co.22.2436 .
  8. Hart MG, Garside R, Rogers G, Stein K, Grant R . Temozolomide for high grade glioma . The Cochrane Database of Systematic Reviews . 2013 . 4 . CD007415 . April 2013 . 23633341 . 6457743 . 10.1002/14651858.CD007415.pub2 .
  9. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma . CA . 60 . 3 . 166–193 . 2010 . 20445000 . 2888474 . 10.3322/caac.20069 .
  10. McKenney AS, Weg E, Bale TA, Wild AT, Um H, Fox MJ, Lin A, Yang JT, Yao P, Birger ML, Tixier F, Sellitti M, Moss NS, Young RJ, Veeraraghavan H . Radiomic Analysis to Predict Histopathologically Confirmed Pseudoprogression in Glioblastoma Patients . English . Advances in Radiation Oncology . 8 . 1 . 100916 . 6 February 2022 . 36711062 . 9873493 . 10.1016/j.adro.2022.100916 . 246647975 .
  11. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial . English . The Lancet. Oncology . 10 . 5 . 459–466 . May 2009 . 19269895 . 10.1016/S1470-2045(09)70025-7 . 25150249 .
  12. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016 . Neuro-Oncology . 21 . Suppl 5 . v1–v100 . November 2019 . 31675094 . 6823730 . 10.1093/neuonc/noz150 .
  13. Book: Schapira AH . Neurology and clinical neuroscience . 2007 . Mosby Elsevier . Philadelphia . 978-0-323-07053-9 . 1336 . live . https://web.archive.org/web/20170729005047/https://books.google.ca/books?id=EwajBQAAQBAJ&pg=PA1336 . 29 July 2017 .
  14. McNeill KA . Epidemiology of Brain Tumors . Neurologic Clinics . 34 . 4 . 981–998 . November 2016 . 27720005 . 10.1016/j.ncl.2016.06.014 .
  15. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017 . Neuro-Oncology . 22 . 12 Suppl 2 . iv1–iv96 . October 2020 . 33123732 . 7596247 . 10.1093/neuonc/noaa200 .
  16. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P . Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study . European Journal of Cancer . 51 . 15 . 2231–2241 . October 2015 . 26421825 . 10.1016/j.ejca.2015.07.032 .
  17. Alifieris C, Trafalis DT . Glioblastoma multiforme: Pathogenesis and treatment . Pharmacology & Therapeutics . 152 . 63–82 . August 2015 . 25944528 . 10.1016/j.pharmthera.2015.05.005 .
  18. Iacob G, Dinca EB . Current data and strategy in glioblastoma multiforme . Journal of Medicine and Life . 2 . 4 . 386–393 . 25 November 2009 . 20108752 . 3019011 .
  19. Smoll . Nicolas R . Brady . Zoe . Scurrah . Katrina J . Lee . Choonsik . Berrington de González . Amy . Mathews . John D . Computed tomography scan radiation and brain cancer incidence . Neuro-Oncology . 6 July 2023 . 25 . 7 . 1368–1376 . 10.1093/neuonc/noad012 . 36638155 . 10326490 .
  20. Smoll . Nicolas R. . Brady . Zoe . Scurrah . Katrina . Mathews . John D. . Exposure to ionizing radiation and brain cancer incidence: The Life Span Study cohort . Cancer Epidemiology . June 2016 . 42 . 60–65 . . 10.1016/j.canep.2016.03.006 . 27038588 .
  21. Ohgaki H, Kleihues P . Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas . Journal of Neuropathology and Experimental Neurology . 64 . 6 . 479–489 . June 2005 . 15977639 . 10.1093/jnen/64.6.479 . free .
  22. Vilchez RA, Kozinetz CA, Arrington AS, Madden CR, Butel JS . Simian virus 40 in human cancers . The American Journal of Medicine . 114 . 8 . 675–684 . June 2003 . 12798456 . 10.1016/S0002-9343(03)00087-1 .
  23. Crawford JR, Santi MR, Thorarinsdottir HK, Cornelison R, Rushing EJ, Zhang H, Yao K, Jacobson S, Macdonald TJ . Detection of human herpesvirus-6 variants in pediatric brain tumors: association of viral antigen in low grade gliomas . Journal of Clinical Virology . 46 . 1 . 37–42 . September 2009 . 19505845 . 2749001 . 10.1016/j.jcv.2009.05.011 .
  24. Chi J, Gu B, Zhang C, Peng G, Zhou F, Chen Y, Zhang G, Guo Y, Guo D, Qin J, Wang J, Li L, Wang F, Liu G, Xie F, Feng D, Zhou H, Huang X, Lu S, Liu Y, Hu W, Yao K . Human herpesvirus 6 latent infection in patients with glioma . The Journal of Infectious Diseases . 206 . 9 . 1394–1398 . November 2012 . 22962688 . 10.1093/infdis/jis513 . free .
  25. McFaline-Figueroa JR, Wen PY . The Viral Connection to Glioblastoma . Current Infectious Disease Reports . 19 . 2 . 5 . February 2017 . 28233187 . 10.1007/s11908-017-0563-z . 30446699 .
  26. El Baba . Ranim . Pasquereau . Sébastien . Haidar Ahmad . Sandy . Monnien . Franck . Abad . Marine . Bibeau . Frédéric . Herbein . Georges . EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes . Oncogene . 9 June 2023 . 42 . 24 . 2031–2045 . 10.1038/s41388-023-02709-3 . 37147437 . 10256614 .
  27. Guyon . Joris . Haidar Ahmad . Sandy . El Baba . Ranim . Le Quang . Mégane . Bikfalvi . Andreas . Daubon . Thomas . Herbein . Georges . Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes . Cancer Gene Therapy . 29 March 2024 . 31 . 7 . 1070–1080 . 10.1038/s41417-024-00767-7 . 38553638 . free . 11257955 .
  28. Huncharek M, Kupelnick B, Wheeler L . Dietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studies . Journal of Environmental Pathology, Toxicology and Oncology . 22 . 2 . 129–137 . 2003 . 14533876 . 10.1615/JEnvPathToxOncol.v22.i2.60 .
  29. Kan P, Simonsen SE, Lyon JL, Kestle JR . Cellular phone use and brain tumor: a meta-analysis . Journal of Neuro-Oncology . 86 . 1 . 71–78 . January 2008 . 17619826 . 10.1007/s11060-007-9432-1 . 23460254 .
  30. Hardell L, Carlberg M, Hansson Mild K . Epidemiological evidence for an association between use of wireless phones and tumor diseases . Pathophysiology . 16 . 2–3 . 113–122 . August 2009 . 19268551 . 10.1016/j.pathophys.2009.01.003 .
  31. Zong H, Verhaak RG, Canoll P . The cellular origin for malignant glioma and prospects for clinical advancements . Expert Review of Molecular Diagnostics . 12 . 4 . 383–394 . May 2012 . 22616703 . 3368274 . 10.1586/erm.12.30 .
  32. Zong H, Parada LF, Baker SJ . Cell of origin for malignant gliomas and its implication in therapeutic development . Cold Spring Harbor Perspectives in Biology . 7 . 5 . a020610 . January 2015 . 25635044 . 4448618 . 10.1101/cshperspect.a020610 .
  33. 10.3390/cancers14020443 . free . Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives . 2022 . Cancers . 14 . 2 . 443 . 35053605 . 8773542 . Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T .
  34. Kazi AZ, Joshi PC, Kelkar AB, Mahajan MS, Ghawate AS . MRI evaluation of pathologies affecting the corpus callosum: A pictorial essay . The Indian Journal of Radiology & Imaging . 23 . 4 . 321–332 . October 2013 . 24604936 . 3932574 . 10.4103/0971-3026.125604 . free .
  35. Book: 10.1007/978-3-642-84988-6_1 . Introduction . Histological Typing of Tumours of the Central Nervous System . 1993 . 1–3 . 978-3-540-56971-8 . Kleihues P, Burger PC, Scheithauer BW .
  36. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P . The 2007 WHO classification of tumours of the central nervous system . Acta Neuropathologica . 114 . 2 . 97–109 . August 2007 . 17618441 . 1929165 . 10.1007/s00401-007-0243-4 .
  37. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary . Acta Neuropathologica . 131 . 6 . 803–820 . June 2016 . 27157931 . 10.1007/s00401-016-1545-1 . free .
  38. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary . Neuro-Oncology . 23 . 8 . 1231–1251 . August 2021 . 34185076 . 8328013 . 10.1093/neuonc/noab106 .
  39. Louis . David N . Perry . Arie . Wesseling . Pieter . Brat . Daniel J . Cree . Ian A . Figarella-Branger . Dominique . Hawkins . Cynthia . Ng . H K . Pfister . Stefan M . Reifenberger . Guido . Soffietti . Riccardo . von Deimling . Andreas . Ellison . David W . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary . Neuro-Oncology . 2 August 2021 . 23 . 8 . 1231–1251 . 10.1093/neuonc/noab106 . 34185076 . 8328013 .
  40. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RG . Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment . Cancer Cell . 32 . 1 . 42–56.e6 . July 2017 . 28697342 . 5599156 . 10.1016/j.ccell.2017.06.003 .
  41. Hayden EC . Genomics boosts brain-cancer work . Nature . 463 . 7279 . 278 . January 2010 . 20090720 . 10.1038/463278a . free .
  42. Sasmita AO, Wong YP, Ling AP . Biomarkers and therapeutic advances in glioblastoma multiforme . Asia-Pacific Journal of Clinical Oncology . 14 . 1 . 40–51 . February 2018 . 28840962 . 10.1111/ajco.12756 . free .
  43. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 . Cancer Cell . 17 . 1 . 98–110 . January 2010 . 20129251 . 2818769 . 10.1016/j.ccr.2009.12.020 .
  44. Kuehn BM . Genomics illuminates a deadly brain cancer . JAMA . 303 . 10 . 925–927 . March 2010 . 20215599 . 10.1001/jama.2010.236 .
  45. Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A . Mutational profiling of kinases in glioblastoma . BMC Cancer . 14 . 1 . 718 . September 2014 . 25256166 . 4192443 . 10.1186/1471-2407-14-718 . free .
  46. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE . The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation . Biochimica et Biophysica Acta (BBA) – Reviews on Cancer . 1846 . 2 . 326–341 . December 2014 . 24880135 . 10.1016/j.bbcan.2014.05.004 .
  47. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R . MGMT gene silencing and benefit from temozolomide in glioblastoma . The New England Journal of Medicine . 352 . 10 . 997–1003 . March 2005 . 15758010 . 10.1056/NEJMoa043331 . free .
  48. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK . Malignant astrocytic glioma: genetics, biology, and paths to treatment . Genes & Development . 21 . 21 . 2683–2710 . November 2007 . 17974913 . 10.1101/gad.1596707 .
  49. Book: 10.1055/b-006-149702 . Handbook of Neurosurgery . 2016 . 978-1-62623-242-6 . Greenberg MS.
  50. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME . Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma . Journal of Clinical Oncology . 26 . 18 . 3015–3024 . June 2008 . 18565887 . 10.1200/JCO.2007.15.7164 . free .
  51. Gilbertson RJ, Rich JN . Making a tumour's bed: glioblastoma stem cells and the vascular niche . Nature Reviews. Cancer . 7 . 10 . 733–736 . October 2007 . 17882276 . 10.1038/nrc2246 . 2634215 .
  52. Book: Brown DV, Stylli SS, Kaye AH, Mantamadiotis T . Stem Cells Heterogeneity in Cancer . Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance . Advances in Experimental Medicine and Biology . 1139 . 1–21 . 2019 . 31134492 . 10.1007/978-3-030-14366-4_1 . 978-3-030-14365-7 . 167220115 .
  53. Annovazzi L, Mellai M, Schiffer D . Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma . Cancers . 9 . 6 . 57 . May 2017 . 28587121 . 5483876 . 10.3390/cancers9060057 . free .
  54. Molenaar RJ . Ion channels in glioblastoma . ISRN Neurology . 2011 . 590249 . 2011 . 22389824 . 3263536 . 10.5402/2011/590249 . free .
  55. Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M . A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion . Molecular Neurobiology . 47 . 1 . 131–144 . February 2013 . 23054677 . 3538124 . 10.1007/s12035-012-8349-7 .
  56. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA, Lawler SE . MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells . Molecular Cell . 37 . 5 . 620–632 . March 2010 . 20227367 . 3125113 . 10.1016/j.molcel.2010.02.018 .
  57. Bhaskaran V, Nowicki MO, Idriss M, Jimenez MA, Lugli G, Hayes JL, Mahmoud AB, Zane RE, Passaro C, Ligon KL, Haas-Kogan D, Bronisz A, Godlewski J, Lawler SE, Chiocca EA, Peruzzi P . The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma . Nature Communications . 10 . 1 . 442 . January 2019 . 30683859 . 6347618 . 10.1038/s41467-019-08390-z . 2019NatCo..10..442B .
  58. Dimberg A . The glioblastoma vasculature as a target for cancer therapy . Biochemical Society Transactions . 42 . 6 . 1647–1652 . December 2014 . 25399584 . 10.1042/BST20140278 .
  59. Jain RK . Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers . Journal of Clinical Oncology . 31 . 17 . 2205–2218 . June 2013 . 23669226 . 3731977 . 10.1200/JCO.2012.46.3653 .
  60. Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW . Patterns of contrast enhancement in the brain and meninges . Radiographics . 27 . 2 . 525–551 . 2007 . 17374867 . 10.1148/rg.272065155 .
  61. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJ, Bleeker FE . The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone . Neuro-Oncology . 16 . 9 . 1263–1273 . September 2014 . 24510240 . 4136888 . 10.1093/neuonc/nou005 .
  62. Eibl RH, Schneemann M . Liquid biopsy and glioblastoma . Exploration of Targeted Anti-Tumor Therapy . 4 . 1 . 28–41 . February 2023 . 36937320 . 10017188 . 10.37349/etat.2023.00121 .
  63. Mo H, Magaki S, Deisch JK, Raghavan R . Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas . Journal of Neuropathology and Experimental Neurology . 81 . 9 . 707–716 . August 2022 . 35856894 . 9614687 . 10.1093/jnen/nlac059 .
  64. Web site: Gliomas Prevention . . . 9 October 2021 . 9 October 2021 . https://web.archive.org/web/20211009193312/https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/gliomas/prevention . live .
  65. Lawson HC, Sampath P, Bohan E, Park MC, Hussain N, Olivi A, Weingart J, Kleinberg L, Brem H . Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience . Journal of Neuro-Oncology . 83 . 1 . 61–70 . May 2007 . 17171441 . 4086528 . 10.1007/s11060-006-9303-1 .
  66. Stevens GH . Antiepileptic therapy in patients with central nervous system malignancies . Current Neurology and Neuroscience Reports . 6 . 4 . 311–318 . July 2006 . 16822352 . 10.1007/s11910-006-0024-9 . 37712742 .
  67. Das S, Marsden PA . Angiogenesis in glioblastoma . The New England Journal of Medicine . 369 . 16 . 1561–1563 . October 2013 . 24131182 . 5378489 . 10.1056/NEJMcibr1309402 . Phimister EG .
  68. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival . Journal of Neurosurgery . 95 . 2 . 190–198 . August 2001 . 11780887 . 10.3171/jns.2001.95.2.0190 .
  69. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial . The Lancet. Oncology . 7 . 5 . 392–401 . May 2006 . 16648043 . 10.1016/S1470-2045(06)70665-9 .
  70. Schatlo B, Fandino J, Smoll NR, Wetzel O, Remonda L, Marbacher S, Perrig W, Landolt H, Fathi AR . Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery . Neuro-Oncology . 17 . 12 . 1560–1567 . December 2015 . 25858636 . 4633924 . 10.1093/neuonc/nov049 .
  71. Rominiyi O, Collis SJ . DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies . Molecular Oncology . 16 . 1 . 11–41 . January 2022 . 34036721 . 8732357 . 10.1002/1878-0261.13020 .
  72. Sinha R, Stephenson JM, Price SJ . A systematic review of cognitive function in patients with glioblastoma undergoing surgery . Neuro-Oncology Practice . 7 . 2 . 131–142 . March 2020 . 32626582 . 7318858 . 10.1093/nop/npz018 .
  73. Pendergrass JC, Targum SD, Harrison JE . Cognitive Impairment Associated with Cancer: A Brief Review . Innovations in Clinical Neuroscience . 15 . 1–2 . 36–44 . February 2018 . 29497579 . 5819720 .
  74. Janelsins MC, Kesler SR, Ahles TA, Morrow GR . Prevalence, mechanisms, and management of cancer-related cognitive impairment . International Review of Psychiatry . 26 . 1 . 102–113 . February 2014 . 24716504 . 4084673 . 10.3109/09540261.2013.864260 .
  75. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter MB, Castel H . Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors . Annals of Oncology . 30 . 12 . 1925–1940 . December 2019 . 31617564 . 8109411 . 10.1093/annonc/mdz410 .
  76. Pendergrass JC, Targum SD, Harrison JE . Cognitive Impairment Associated with Cancer: A Brief Review . Innovations in Clinical Neuroscience . 15 . 1–2 . 36–44 . February 2018 . 29497579 . 5819720 .
  77. Biegler KA, Chaoul MA, Cohen L . Cancer, cognitive impairment, and meditation . Acta Oncologica . 48 . 1 . 18–26 . 2009 . 19031161 . 10.1080/02841860802415535 .
  78. Khosla D . Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma . Annals of Translational Medicine . 4 . 3 . 54 . February 2016 . 26904576 . 4740000 . 10.3978/j.issn.2305-5839.2016.01.25 .
  79. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial . Journal of Neurosurgery . 49 . 3 . 333–343 . September 1978 . 355604 . 10.3171/jns.1978.49.3.0333 .
  80. Showalter TN, Andrel J, Andrews DW, Curran WJ, Daskalakis C, Werner-Wasik M . Multifocal glioblastoma multiforme: prognostic factors and patterns of progression . International Journal of Radiation Oncology, Biology, Physics . 69 . 3 . 820–824 . November 2007 . 17499453 . 10.1016/j.ijrobp.2007.03.045 .
  81. Fulton DS, Urtasun RC, Scott-Brown I, Johnson ES, Mielke B, Curry B, Huyser-Wierenga D, Hanson J, Feldstein M . Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study . Journal of Neuro-Oncology . 14 . 1 . 63–72 . September 1992 . 1335044 . 10.1007/BF00170946 . 24245934 .
  82. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM . Improving the radiosensitivity of radioresistant and hypoxic glioblastoma . Future Oncology . 6 . 10 . 1591–1601 . October 2010 . 21062158 . 10.2217/fon.10.123 .
  83. , accessed 1 February 2016
  84. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma . The New England Journal of Medicine . 352 . 10 . 987–996 . March 2005 . 15758009 . 10.1056/NEJMoa043330 . 41340212 . European Organisation for Research Treatment of Cancer Brain Tumor Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group . free .
  85. 10.1017/S1748232105000054 . Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme . 2006 . Progress in Neurotherapeutics and Neuropsychopharmacology . 1 . 37–52 . Mason WP, Mirimanoff RO, Stupp R .
  86. Web site: Temozolomide Plus Radiation Helps Brain Cancer – National Cancer Institute . 15 September 2007 . dead . https://web.archive.org/web/20070815232444/http://www.cancer.gov/clinicaltrials/results/glioblastoma0604 . 15 August 2007 .
  87. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE . Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma . Journal of Neuro-Oncology . 82 . 1 . 81–83 . March 2007 . 16944309 . 10.1007/s11060-006-9241-y . 6262668 .
  88. Dall'oglio S, D'Amico A, Pioli F, Gabbani M, Pasini F, Passarin MG, Talacchi A, Turazzi S, Maluta S . Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas . Journal of Neuro-Oncology . 90 . 3 . 315–319 . December 2008 . 18688571 . 10.1007/s11060-008-9663-9 . 21517366 .
  89. Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M . Anti-angiogenic therapy for high-grade glioma . The Cochrane Database of Systematic Reviews . 2018 . 11 . CD008218 . November 2018 . 30480778 . 6516839 . 10.1002/14651858.CD008218.pub4 . The use of anti-angiogenic therapy does not significantly improve overall survival in newly diagnosed people with glioblastoma. Thus, there is insufficient evidence to support the use of anti-angiogenic therapy for people with newly diagnosed glioblastoma at this time. .
  90. Hanna C, Lawrie TA, Rogozińska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R . Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis . The Cochrane Database of Systematic Reviews . 2020 . 3 . CD013261 . March 2020 . 32202316 . 7086476 . 10.1002/14651858.cd013261.pub2 .
  91. Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ . Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them . British Journal of Cancer . 127 . 6 . 976–987 . October 2022 . 35662275 . 9470562 . 10.1038/s41416-022-01864-w .
  92. Web site: FDA approves expanded indication for medical device to treat a form of brain cancer . . 19 March 2016 . live . https://web.archive.org/web/20160323083354/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm . 23 March 2016 .
  93. Web site: FDA approval letter – NovoTTF-100A System . www.fda.gov . 26 December 2014 . live . https://web.archive.org/web/20150922095543/http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034a.pdf . 22 September 2015 .
  94. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z . Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial . JAMA . 314 . 23 . 2535–2543 . December 2015 . 26670971 . 10.1001/jama.2015.16669 . free .
  95. Sampson JH . Alternating Electric Fields for the Treatment of Glioblastoma . JAMA . 314 . 23 . 2511–2513 . December 2015 . 26670969 . 10.1001/jama.2015.16701 .
  96. Wick W . TTFields: where does all the skepticism come from? . Neuro-Oncology . 18 . 3 . 303–305 . March 2016 . 26917587 . 4767251 . 10.1093/neuonc/now012 .
  97. Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ . Tumour treating fields therapy for glioblastoma: current advances and future directions . British Journal of Cancer . 124 . 4 . 697–709 . February 2021 . 33144698 . 7884384 . 10.1038/s41416-020-01136-5 .
  98. Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I . Epidemiology of Glioblastoma Multiforme-Literature Review . Cancers . 14 . 10 . 2412 . May 2022 . 35626018 . 9139611 . 10.3390/cancers14102412 . free .
  99. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ . Improved survival time trends for glioblastoma using the SEER 17 population-based registries . Journal of Neuro-Oncology . 107 . 1 . 207–212 . March 2012 . 21984115 . 4077033 . 10.1007/s11060-011-0738-7 .
  100. Smoll NR, Schaller K, Gautschi OP . Long-term survival of patients with glioblastoma multiforme (GBM) . Journal of Clinical Neuroscience . 20 . 5 . 670–675 . May 2013 . 23352352 . 10.1016/j.jocn.2012.05.040 . 5088829 .
  101. Caruso R, Pesce A, Wierzbicki V . A very rare case report of long-term survival: A patient operated on in 1994 of glioblastoma multiforme and currently in perfect health . International Journal of Surgery Case Reports . 33 . 41–43 . 20 February 2017 . 28273605 . 5338899 . 10.1016/j.ijscr.2017.02.025 .
  102. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G . Long-term survival with glioblastoma multiforme . Brain . 130 . Pt 10 . 2596–2606 . October 2007 . 17785346 . 10.1093/brain/awm204 . free .
  103. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M . Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme . Journal of Neuro-Oncology . 83 . 1 . 91–93 . May 2007 . 17164975 . 10.1007/s11060-006-9292-0 . 34370292 .
  104. Smoll NR, Schaller K, Gautschi OP . The cure fraction of glioblastoma multiforme . Neuroepidemiology . 39 . 1 . 63–69 . 2012 . 22776797 . 10.1159/000339319 . free .
  105. Web site: University of California, Los Angeles Neuro-Oncology : How Our Patients Perform : Glioblastoma Multiforme [GBM] ]. https://web.archive.org/web/20120609070823/http://www.neurooncology.ucla.edu/Performance/GlioblastomaMultiforme.aspx . 9 June 2012. . Neurooncology.ucla.edu. Retrieved on 19 October 2010.
  106. Shaw EG, Seiferheld W, Scott C, Coughlin C, Leibel S, Curran W, Mehta M . 10.1016/S0360-3016(03)00843-5 . Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients . 2003 . International Journal of Radiation Oncology, Biology, Physics . 57 . 2 . S135–36 . free .
  107. Xu H, Chen J, Xu H, Qin Z . Geographic Variations in the Incidence of Glioblastoma and Prognostic Factors Predictive of Overall Survival in US Adults from 2004–2013 . Frontiers in Aging Neuroscience . 9 . 352 . 2017 . 29163134 . 5681990 . 10.3389/fnagi.2017.00352 . free .
  108. Philips A, Henshaw DL, Lamburn G, O'Carroll MJ . Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor . Journal of Environmental and Public Health . 2018 . 7910754 . 2018 . 30034480 . 6035820 . 10.1155/2018/7910754 . free .
  109. Siegel DA, Li J, Henley SJ, Wilson RJ, Lunsford NB, Tai E, Van Dyne EA . Geographic Variation in Pediatric Cancer Incidence – United States, 2003–2014 . en-us . MMWR. Morbidity and Mortality Weekly Report . 67 . 25 . 707–713 . June 2018 . 29953430 . 6023185 . 10.15585/mmwr.mm6725a2 .
  110. Bailey & Cushing: Tumors of the Glioma Group. JB Lippincott, Philadelphia, 1926.
  111. Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, Mukherjee A, Mandal M . Insights into molecular therapy of glioma: current challenges and next generation blueprint . Acta Pharmacologica Sinica . 38 . 5 . 591–613 . May 2017 . 28317871 . 5457688 . 10.1038/aps.2016.167 .
  112. Tobias A, Ahmed A, Moon KS, Lesniak MS . The art of gene therapy for glioma: a review of the challenging road to the bedside . Journal of Neurology, Neurosurgery, and Psychiatry . 84 . 2 . 213–222 . February 2013 . 22993449 . 3543505 . 10.1136/jnnp-2012-302946 .
  113. Fulci G, Chiocca EA . The status of gene therapy for brain tumors . Expert Opinion on Biological Therapy . 7 . 2 . 197–208 . February 2007 . 17250458 . 2819130 . 10.1517/14712598.7.2.197 .
  114. Borchers A, Pieler T . Programming pluripotent precursor cells derived from Xenopus embryos to generate specific tissues and organs . Genes . 1 . 3 . 413–426 . November 2010 . 24710095 . 10.3390/chemosensors8040117 . MDPI AG . 3966229 . free .
  115. Wu SQ, Yang CX, Yan XP . A Dual-Functional Persistently Luminescent Nanocomposite Enables Engineering of Mesenchymal Stem Cells for Homing and Gene Therapy of Glioblastoma . Advanced Functional Materials . March 2017 . 27 . 11 . 1604992 . 10.1002/adfm.201604992 . 99147218 .
  116. Hossain JA, Marchini A, Fehse B, Bjerkvig R, Miletic H . Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects . Neuro-Oncology Advances . 2 . 1 . vdaa013 . 1 January 2020 . 32642680 . 7212909 . 10.1093/noajnl/vdaa013 .
  117. Suryawanshi YR, Schulze AJ . Oncolytic Viruses for Malignant Glioma: On the Verge of Success? . Viruses . 13 . 7 . 1294 . July 2021 . 34372501 . 8310195 . 10.3390/v13071294 . free .
  118. van Woensel M, Wauthoz N, Rosière R, Amighi K, Mathieu V, Lefranc F, van Gool SW, de Vleeschouwer S . Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM? . Cancers . 5 . 3 . 1020–1048 . August 2013 . 24202332 . 3795377 . 10.3390/cancers5031020 . free .
  119. Pardeshi CV, Belgamwar VS . Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting . Expert Opinion on Drug Delivery . 10 . 7 . 957–972 . July 2013 . 23586809 . 10.1517/17425247.2013.790887 . 8020921 .
  120. Peterson A, Bansal A, Hofman F, Chen TC, Zada G . A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option . Journal of Neuro-Oncology . 116 . 3 . 437–446 . February 2014 . 24398618 . 10.1007/s11060-013-1346-5 . 2414770 .
  121. Chen TC, Fonseca CO, Schönthal AH . Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy . American Journal of Cancer Research . 5 . 5 . 1580–1593 . 2015 . 26175929 . 4497427 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Glioblastoma".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.